
|Articles|February 1, 2004
Topical stymies HIV
Washington - As the number of new cases of human immunodeficiency virus continues to grow, a topical microbicide might offer hope. Applied intravaginally, the agent has completely blocked intravaginal transmission of Simian Immunodeficiency Virus to female monkeys, according to Andrew Blauvelt, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















